MCID: CLL014
MIFTS: 45

Cll/sll

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Cll/sll

MalaCards integrated aliases for Cll/sll:

Name: Cll/sll 12 15
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:6354
NCIt 49 C27911
UMLS 71 C1302547

Summaries for Cll/sll

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.

MalaCards based summary : Cll/sll, also known as chronic lymphocytic leukemia/small lymphocytic lymphoma, is related to leukemia, chronic lymphocytic 2 and anemia, autoimmune hemolytic, and has symptoms including fatigue An important gene associated with Cll/sll is ZAP70 (Zeta Chain Of T Cell Receptor Associated Protein Kinase 70), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Zanubrutinib and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Related Diseases for Cll/sll

Diseases related to Cll/sll via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 2 30.7 ZAP70 CD5 CD38 ATM
2 anemia, autoimmune hemolytic 30.5 ZAP70 IGHV4-38-2 CD5 CD19 CCR6
3 macroglobulinemia 30.3 TP53 PAX5 BTK
4 thyroid lymphoma 30.3 TP53 MME CD5 BCL6
5 merkel cell carcinoma 30.3 TP53 PDCD1 PAX5
6 plasmablastic lymphoma 30.1 CD38 BCL6
7 myelodysplastic syndrome 30.1 TP53 PDCD1 EZH2 CD38 BTK ATM
8 agammaglobulinemia 30.1 CD79B CD79A CD19 BTK
9 richter's syndrome 30.0 ZAP70 TP53 SPN IGHV4-38-2 CD5 CD38
10 prolymphocytic leukemia 29.7 ZAP70 TP53 CD5 CD38 CD19 CCND1
11 hairy cell leukemia 29.6 TP53 CD5 CD38 CD22 CCND1
12 nodal marginal zone lymphoma 29.6 SPN MME IGHV4-38-2 CD5 BCL6
13 lymphoplasmacytic lymphoma 29.5 ZAP70 PAX5 CD5 CCND1 BTK
14 autoimmune disease 29.5 ZAP70 PDCD1 CD79A CD22 CCR6
15 myeloid sarcoma 29.4 SPN PAX5 CD79A
16 lymphoblastic lymphoma 29.4 TP53 PAX5 MME CD5 BCL6
17 follicular lymphoma 29.3 PAX5 MME EZH2 CD5 CCND1 BCL6
18 peripheral t-cell lymphoma 28.4 TP53 PDCD1 PAX5 MME CD5 CD38
19 composite lymphoma 28.3 SPN PAX5 MME IGHV4-38-2 CD79A CD5
20 lymphoma 27.8 TP53 PDCD1 PAX5 MME EZH2 CD5
21 mantle cell lymphoma 27.7 TP53 SPN PAX5 MME EZH2 CD5
22 b-cell lymphoma 27.4 ZAP70 TP53 PAX5 MME EZH2 CD79B
23 hematologic cancer 27.3 ZAP70 TP53 PAX5 MME IGHV4-38-2 CD5
24 leukemia, acute lymphoblastic 27.3 ZAP70 TP53 PAX5 MME IGHV4-38-2 CD5
25 diffuse large b-cell lymphoma 26.6 TP53 SPN PDCD1 PAX5 MME EZH2
26 myeloma, multiple 26.0 TP53 PAX5 MME IGHV4-38-2 EZH2 CD79A
27 leukemia, chronic lymphocytic 25.5 ZAP70 TP53 SPN SLC35B2 PAX5 MME
28 marginal zone b-cell lymphoma 25.4 SPN SLC35B2 PAX5 MME IGHV4-38-2 CD79B
29 leukemia, acute myeloid 25.1 TP53 SPN PAX5 MME IGHV4-38-2 EZH2
30 lymphoma, non-hodgkin, familial 25.0 TP53 SPN PAX5 MME IGHV4-38-2 EZH2
31 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.6
32 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.6
33 thrombocytopenia 10.5
34 cecum lymphoma 10.5 TP53 MME
35 lymphoma, hodgkin, classic 10.4
36 neutropenia 10.4
37 chromosomal triplication 10.4
38 hemolytic anemia 10.4
39 congenital hypogammaglobulinemia 10.4 CD19 BTK
40 hilar lung carcinoma 10.4 MME CD79A
41 lung hilum cancer 10.4 MME CD79A
42 cervical adenoma malignum 10.4 TP53 MME ATM
43 lymphoproliferative syndrome 10.4
44 thrombocytopenia due to platelet alloimmunization 10.4
45 lymphadenitis 10.4
46 langerhans cell sarcoma 10.4
47 herpes simplex 10.4
48 maxillary sinus adenocarcinoma 10.4 TP53 ATM
49 esophageal leukoplakia 10.4 TP53 CCND1
50 endocrine exophthalmos 10.4 MME CD5 ATM

Graphical network of the top 20 diseases related to Cll/sll:



Diseases related to Cll/sll

Symptoms & Phenotypes for Cll/sll

UMLS symptoms related to Cll/sll:


fatigue

GenomeRNAi Phenotypes related to Cll/sll according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ATM BCL6 CCND1 CCR6 CD22 CD5

MGI Mouse Phenotypes related to Cll/sll:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 ATM BCL6 BTK CCND1 CCR6 CD19
2 cellular MP:0005384 10.28 ATM BCL6 BTK CCND1 CD19 CD22
3 immune system MP:0005387 10.28 ATM BCL6 BTK CCND1 CCR6 CD19
4 homeostasis/metabolism MP:0005376 10.18 ATM BCL6 BTK CCND1 CCR6 CD19
5 integument MP:0010771 9.96 ATM BCL6 BTK CCND1 CD19 CD5
6 neoplasm MP:0002006 9.85 ATM BTK CCND1 CD19 CD79A EZH2
7 nervous system MP:0003631 9.73 ATM CCND1 CCR6 CD19 CD22 CD5
8 normal MP:0002873 9.36 BCL6 CCND1 CCR6 CD19 CD5 CD79A

Drugs & Therapeutics for Cll/sll

Drugs for Cll/sll (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
4
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
5 Anti-HIV Agents Phase 3
6 Anti-Retroviral Agents Phase 3
7 Reverse Transcriptase Inhibitors Phase 3
8
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
9
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560 441411
10
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
11
Adenosine Approved, Investigational Phase 2 58-61-7 60961
12
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
13
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
14
Auranofin Approved, Investigational Phase 2 34031-32-8 6918453 6333901
15
Iodine Approved, Investigational Phase 2 7553-56-2 807
16
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
17
Vincristine Approved, Investigational Phase 1, Phase 2 57-22-7, 2068-78-2 5978
18
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
19
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
20
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
21
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
22
Melphalan Approved Phase 2 148-82-3 460612 4053
23
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
24
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
25
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
26
Allopurinol Approved Phase 2 315-30-0 2094
27
tannic acid Approved Phase 2 1401-55-4
28
Promethazine Approved, Investigational Phase 2 60-87-7 4927
29
Acetaminophen Approved Phase 2 103-90-2 1983
30
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
31
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
32
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
33
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
34
Mycophenolic acid Approved Phase 2 24280-93-1 446541
35
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
38
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
39
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
40
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
41
nivolumab Approved Phase 2 946414-94-4
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
45
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
46 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
47
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
48
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
2 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
3 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
4 Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01722487 Phase 3 Ibrutinib;Chlorambucil
5 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting NCT03734016 Phase 3 Zanubrutinib;Ibrutinib
6 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
7 An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT03336333 Phase 3 Zanubrutinib;Bendamustine;Rituximab;Venetoclax
8 A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Recruiting NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
9 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO) Active, not recruiting NCT02004522 Phase 3 Duvelisib;Ofatumumab
10 An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil) Active, not recruiting NCT01724346 Phase 3 Post-Chlorambucil Therapy Follow-up;Ibrutinib;Second-line Ibrutinib;Alternative Anticancer Treatment;Alternative Anti-cancer Treatment
11 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Enrolling by invitation NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
12 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
13 Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study Not yet recruiting NCT04269902 Phase 3 Venetoclax
14 An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
15 A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00193518 Phase 2 Arsenic Trioxide
16 A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma Completed NCT01403636 Phase 2 SAR245409
17 Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial Completed NCT03041636 Phase 2 Ruxolitinib;Ruxolitinib Phosphate
18 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
19 Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
20 A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00439231 Phase 2 Lenalidomide
21 Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00873457 Phase 2 perifosine
22 A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia Completed NCT01105247 Phase 1, Phase 2 PCI-32765
23 Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study Completed NCT00935792 Phase 1, Phase 2 alemtuzumab;everolimus
24 Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01113632 Phase 2 Ofatumumab
25 Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00290004 Phase 1, Phase 2 motexafin gadolinium
26 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
27 Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL) Completed NCT02309515 Phase 2 Lenalidomide
28 Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Completed NCT01024010 Phase 2 Cyclophosphamide;Pentostatin
29 Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma Completed NCT00278161 Phase 2 Cyclophosphamide
30 Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Pentostatin, Alemtuzumab, and Low Dose Rituximab: A Phase II Clinical Trial Completed NCT00669318 Phase 2 pentostatin;sargramostim
31 Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL Completed NCT00974233 Phase 2 Bendamustine;Rituximab;Lenalidomide
32 A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01109069 Phase 2 PCI-32765
33 A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL) Completed NCT01419691 Phase 2 auranofin
34 An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17) Completed NCT01744691 Phase 2 Ibrutinib
35 Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Completed NCT00193466 Phase 2 Rituximab;Fludarabine;CAMPTH-1H
36 A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission Completed NCT00476047 Phase 2
37 A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Completed NCT00918723 Phase 1, Phase 2 Fludarabine Phosphate;Cyclophosphamide;Vorinostat
38 Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Completed NCT01002755 Phase 2 Lenalidomide
39 Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia Completed NCT00438854 Phase 2 Dasatinib
40 Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT02481297 Phase 2 Lirilumab;Rituximab
41 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies Recruiting NCT03037645 Phase 1, Phase 2 SNS-062
42 A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) Recruiting NCT03740529 Phase 1, Phase 2 LOXO-305;Venetoclax;Rituximab;R-CHOP
43 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies Recruiting NCT02988466 Phase 2 GVHD Prophylaxis
44 A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT01066663 Phase 1, Phase 2 pyrimethamine
45 Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL Recruiting NCT03788291 Phase 2 Acalabrutinib;Rituximab
46 A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies Recruiting NCT03088878 Phase 1, Phase 2 Cirmtuzumab;Ibrutinib;Cirmtuzumab plus ibrutinib
47 Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT04209621 Phase 2 Duvelisib;Ibrutinib
48 An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting NCT03331198 Phase 1, Phase 2
49 A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib Recruiting NCT04116437 Phase 2 Zanubrutinib
50 Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression Recruiting NCT03516617 Phase 2 Acalabrutinib

Search NIH Clinical Center for Cll/sll

Genetic Tests for Cll/sll

Anatomical Context for Cll/sll

MalaCards organs/tissues related to Cll/sll:

40
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Thyroid, Breast

Publications for Cll/sll

Articles related to Cll/sll:

(show top 50) (show all 569)
# Title Authors PMID Year
1
Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions. 61
31575355 2020
2
A case of classical Hodgkin Lymphoma-type of Richter Transformation with prolonged survival: Fine-Needle Aspiration findings and mimickers. 61
32492252 2020
3
Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma with Colonization of Germinal Center Follicles. 61
32506455 2020
4
Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes. 61
31523805 2020
5
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. 61
31964785 2020
6
Assessing Cancer Treatment Information Using Medicare and Hospital Discharge Data among Women with Non-Hodgkin Lymphoma in a Los Angeles County Case-Control Study. 61
32066614 2020
7
Orbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance. 61
32363993 2020
8
Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia: Case report for a new perspective on Richter syndrome. 61
32384485 2020
9
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? 61
32253666 2020
10
Bilateral breast implant associated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A case report. 61
32497784 2020
11
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. 61
32393328 2020
12
Subcutaneous Masses as an Unusual Manifestation of Relapse in a Case of Atypical Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation and Complex Karyotype: A Diagnostic Dilemma and Treatment Challenge. 61
32388531 2020
13
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. 61
32249238 2020
14
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. 61
32207333 2020
15
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. 61
31876911 2020
16
Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 61
31544558 2020
17
Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. 61
31953940 2020
18
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. 61
31628428 2020
19
Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). 61
32175786 2020
20
Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma; Small Cell Variant: A Real Diagnostic Challenge. Case Presentation and Review of Literature. 61
32150530 2020
21
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. 61
32209572 2020
22
Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 61
32011965 2020
23
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. 61
32023533 2020
24
Concurrent cutaneous localization of Langerhans cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with a history of chronic lymphocytic leukemia/small lymphocytic lymphoma. 61
31441945 2020
25
Elucidation of binding interactions and mechanism of Fludarabine with dsDNA via multispectroscopic and molecular docking studies. 61
31791837 2020
26
Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study. 61
32049797 2020
27
Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. 61
31884334 2020
28
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications. 61
31612754 2020
29
Hematological malignancies in East Africa-Which cancers to expect and how to provide services. 61
32374771 2020
30
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. 61
32158088 2020
31
Synchronous high-grade bladder carcinoma associated with chronic lymphocytic leukemia: A rare entity in Indian literature. 61
32362634 2020
32
An Unusual Presentation of Richter's Transformation of Chronic Lymphocytic Leukemia in Liver and Lung on 18F-Labeled Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography. 61
31949376 2020
33
Synchronous Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Metastatic Squamous Cell Carcinoma of the Cervix Involving the Coronary Arteries Leading to Acute Myocardial Infarction. 61
32158573 2020
34
Cardiac Myxoma with Cerebral Metastases and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Review. 61
32051810 2020
35
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. 61
31512258 2019
36
Ibrutinib in CLL/SLL: From bench to bedside (Review). 61
31638169 2019
37
Hepatitis C virus and risk of extrahepatic malignancies: a case-control study. 61
31857595 2019
38
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. 61
31554637 2019
39
Merkel cell carcinoma mimicking transformed chronic lymphocytic leukemia/small lymphocytic lymphoma. 61
31788294 2019
40
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 61
31420873 2019
41
Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group. 61
31026087 2019
42
The Role of PI3K Inhibition in Lymphoid Malignancies. 61
31359259 2019
43
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. 61
31340982 2019
44
[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review]. 61
31648477 2019
45
Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada. 61
31325731 2019
46
Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype. 61
30916804 2019
47
Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. 61
30912696 2019
48
CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. 61
31054894 2019
49
Bone Marrow Immunohistochemistry and Flow Cytometry in the Diagnosis of Malignant Hematologic Diseases With Emphasis on Lymphomas: A Comparative Retrospective Study. 61
31290784 2019
50
Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. 61
31262739 2019

Variations for Cll/sll

Expression for Cll/sll

Search GEO for disease gene expression data for Cll/sll.

Pathways for Cll/sll

Pathways related to Cll/sll according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 ZAP70 TP53 PDCD1 MME CD79B CD79A
2
Show member pathways
13.34 ZAP70 TP53 PDCD1 CD79B CD79A CD22
3
Show member pathways
12.57 TP53 CD79B CD79A CD22 CD19 BTK
4
Show member pathways
12.41 CD79B CD79A CD22 CD19 BTK BCL6
5
Show member pathways
12.3 ZAP70 CD22 CD19 BTK BCL6
6
Show member pathways
12.24 CD79B CD79A CD22 CD19 BTK BCL6
7 12.15 TP53 PAX5 BCL6 ATM
8 12.07 ZAP70 PDCD1 PAX5 CD79A CD38 CD19
9 11.86 TP53 CCND1 BCL6 ATM
10
Show member pathways
11.68 CD79B CD79A CD22 CD19 BTK
11 11.6 SPN MME CD38 CD19
12 11.55 MME CD5 CD38 CD22 CD19
13 11.42 TP53 CCND1 ATM
14 11.36 TP53 CCND1 ATM
15 11.29 SPN MME CD79B CD79A CD5 CD38
16 11.2 ZAP70 CD79A CD19 BTK
17 11.19 TP53 CCND1 ATM

GO Terms for Cll/sll

Cellular components related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 SPN MME CD79B CD5 CD22 CD19
2 membrane raft GO:0045121 9.35 ZAP70 MME CD79A CD19 BTK
3 external side of plasma membrane GO:0009897 9.23 PDCD1 IGHV4-38-2 CD79B CD79A CD5 CD22
4 B cell receptor complex GO:0019815 9.16 CD79B CD79A

Biological processes related to Cll/sll according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.81 PDCD1 CD22 CD19 BCL6
2 regulation of cell proliferation GO:0042127 9.8 ZAP70 TP53 EZH2 BCL6
3 adaptive immune response GO:0002250 9.8 ZAP70 PDCD1 CD79B CD79A CD19 BTK
4 immune system process GO:0002376 9.76 ZAP70 PDCD1 CD79B CD79A CD19 BTK
5 B cell differentiation GO:0030183 9.7 CD79B CD79A BCL6
6 apoptotic signaling pathway GO:0097190 9.65 CD5 CD38 BTK
7 humoral immune response GO:0006959 9.58 PDCD1 PAX5 CCR6
8 positive regulation of histone deacetylation GO:0031065 9.55 TP53 BCL6
9 regulation of B cell receptor signaling pathway GO:0050855 9.54 PAX5 CD19
10 T cell migration GO:0072678 9.46 ZAP70 CCR6
11 mitotic G1 DNA damage checkpoint GO:0031571 9.43 TP53 CCND1
12 replicative senescence GO:0090399 9.43 TP53 MME ATM
13 regulation of T cell migration GO:2000404 9.37 SPN CCR6
14 B cell activation GO:0042113 9.26 ZAP70 CD79A CD22 BTK
15 B cell receptor signaling pathway GO:0050853 9.1 IGHV4-38-2 CD79B CD79A CD38 CD19 BTK

Molecular functions related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 TP53 CD79B CD79A CD38 BTK BCL6

Sources for Cll/sll

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....